Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.5K
Overview
51.5K
Cancer Vaccines01:30

Cancer Vaccines

1.0K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

269
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
269
Hepatic Portal System01:21

Hepatic Portal System

5.7K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

224
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
224
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

562
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
562

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

US Preventive Services Task Force: What Does the Future Hold?

American family physician·2026
Same author

Advisory Committee on Immunization Practices Standards for Assessing Evidence.

JAMA·2025
Same author

Practice Alert: Meningococcal Vaccines.

American family physician·2025
Same author

Practice Alert: Pneumococcal Conjugate Vaccines Approved for Adults.

American family physician·2025
Same author

Practice Alert: CDC Guidelines on Doxycycline for STI Postexposure Prophylaxis.

American family physician·2024
Same author

Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

MMWR. Morbidity and mortality weekly report·2024
Same journal

Does taking BP medicine at night (vs morning) result in fewer cardiovascular events?

The Journal of family practice·2023
Same journal

Preventing RSV in children and adults: A vaccine update.

The Journal of family practice·2023
Same journal

Essential oils: How safe? How effective?

The Journal of family practice·2023
Same journal

51-year-old woman • History of Graves disease • General fatigue, palpitations, and hand tremors • Dx?

The Journal of family practice·2023
Same journal

Renewing the dream.

The Journal of family practice·2023
Same journal

55-year-old woman • Myalgias and progressive symmetrical proximal weakness • History of unilateral renal agenesis, type 2 diabetes, and hyperlipidemia • Dx?

The Journal of family practice·2023
See all related articles

Related Experiment Video

Updated: Jan 27, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Hepatitis vaccination update.

Doug Campos-Outcalt1

  • 1University of Arizona, Phoenix, AZ, USA.

The Journal of Family Practice
|March 15, 2019
PubMed
Summary
This summary is machine-generated.

Suboptimal hepatitis B immunization rates may improve with a new 2-dose vaccine. For adults over 40, hepatitis A vaccine is now the preferred post-exposure prophylaxis.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K

Related Experiment Videos

Last Updated: Jan 27, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K

Area of Science:

  • Hepatology
  • Vaccinology
  • Infectious Diseases

Background:

  • Hepatitis B virus (HBV) infection remains a significant global health concern.
  • Current immunization strategies for hepatitis B have not achieved optimal coverage rates.
  • Hepatitis A virus (HAV) infection is a common cause of acute liver inflammation.

Discussion:

  • A novel 2-dose hepatitis B vaccine regimen is being evaluated for its potential to increase immunization uptake.
  • The effectiveness and safety of this new regimen are critical for public health impact.
  • Hepatitis A vaccine is now recommended as the preferred post-exposure prophylaxis for adults aged over 40 years, reflecting updated clinical guidelines.

Key Insights:

  • A new 2-dose hepatitis B vaccine shows promise for improving suboptimal immunization rates.
  • Updated guidelines recommend hepatitis A vaccine for post-exposure prophylaxis in adults over 40.
  • These advancements aim to enhance control strategies for viral hepatitis.

Outlook:

  • Further research is needed to confirm the long-term efficacy and widespread adoption of the 2-dose hepatitis B vaccine.
  • Monitoring the impact of these changes on hepatitis B and A infection incidence is crucial.
  • These developments could lead to improved population-level immunity against hepatitis B and A.